Horse Chestnut
SapindaceaeAesculus hippocastanum
Also known as: Conker Tree, Buckeye, Marronnier
clinical_notes Clinical Summary
Horse Chestnut seed extract (HCSE), standardised to 16–20% aescin, is one of the best-evidenced herbal medicines for chronic venous insufficiency (CVI), with 17 RCTs and multiple Cochrane reviews confirming clinically meaningful reductions in leg oedema, pain, pruritus, and leg circumference — with efficacy comparable to compression therapy.
Aescin acts primarily by inhibiting elastase and hyaluronidase, protecting capillary wall integrity, and enhancing venous tone.
Clinicians must use only standardised extracts (aesculin removed), avoid use in renal and hepatic disease, monitor liver enzymes with prolonged use, and never use raw preparations.
Pregnancy Safety
Standardised HCSE (with aesculin removed) has been used in clinical trials including pregnant women without apparent harm, but no controlled pregnancy safety studies have been conducted. WHO (2004) advises against use in pregnancy due to insufficient safety data. The raw horse chestnut (seed, bark, leaf) is toxic and must never be used in pregnancy.
Lactation Safety
Safety in lactation is not established. Avoid use during breastfeeding. Raw preparations are absolutely contraindicated.
warning Contraindications
- Severe hepatic impairment (contraindicated)Clinically Proven
- Renal impairment / kidney disease (contraindicated)Clinically Proven
- Latex allergy (caution)Clinically Proven
- Concurrent anticoagulant/antiplatelet therapy (caution)Theoretical
vital_signs Clinical Profile
Primary Indications
- check_circle chronic venous insufficiency (CVI)
- check_circle varicose veins
- check_circle leg oedema
- check_circle leg pain and heaviness
- check_circle haemorrhoids
- check_circle post-surgical oedema
- check_circle sports injury oedema
- check_circle male infertility associated with varicocele
Therapeutic Actions
System Affinities
- check_circle venous system
- check_circle lymphatic system
- check_circle musculoskeletal system
- check_circle connective tissue
labs Active Constituents
aescin (escin) — triterpene saponin mixture
aesculin
fraxin
flavonoids
proanthocyanidins
tannins
sterols
fatty acids
history_edu Traditional Use
No TCM data available for this herb yet.
Traditional Uses Across Healing Systems
While many herbs lack controlled clinical trials, centuries of traditional practice across cultures provide valuable insight into their therapeutic applications.
Traditionally used throughout Europe for venous disorders, varicose veins, haemorrhoids, and leg oedema. Seeds and bark used in poultices for arthritis and joint pain.
Modern phytotherapy focuses on standardised seed extract (16–20% aescin). EMA-approved for symptomatic treatment of CVI. Topical aescin gel widely used in Europe for sports injuries and bruising.
spa Parts Used
seed
- chronic venous insufficiency
- varicose veins
- leg oedema
- haemorrhoids
- post-operative oedema
ONLY standardised seed extract (standardised to 16–20% aescin, aesculin removed) should be used medicinally. Raw seeds are toxic. Standard oral dose: 300 mg extract (50 mg aescin) BID. Topical: 2% aescin gel applied TID–QID to affected areas. Never consume raw horse chestnuts — fatal poisonings documented.
shield Safety
Contraindications — Evidence Basis
Severe hepatic impairment
Aescin is hepatically metabolised and case reports of drug-induced liver injury (DILI) exist with horse chestnut seed extract. Contraindicated in severe liver disease; exercise caution in mild-to-moderate hepatic impairment.
Renal impairment / kidney disease
Aescin is partially renally excreted. Reports of worsening renal function with IV aescin in patients with pre-existing renal disease. Horse chestnut should be avoided in kidney disease.
Latex allergy
Cross-reactivity with latex has been documented; individuals with latex allergy may experience allergic reactions to horse chestnut. Assess allergy history before prescribing.
Concurrent anticoagulant/antiplatelet therapy
Aesculin (a coumarin compound in unpurified preparations) has anticoagulant properties. Standardised extracts remove aesculin, but additive bleeding risk remains theoretical with anticoagulants and NSAIDs due to aescin platelet effects.
Monitoring Parameters
Monitor during use, especially with prolonged or high-dose therapy.
Liver enzymes (ALT, AST)
Baseline; at 6–8 weeks if used long-term; annually with continued useCase reports of DILI (drug-induced liver injury) with horse chestnut seed extract necessitate periodic hepatic monitoring, particularly with prolonged use or in patients with risk factors.
flagThreshold: ALT or AST >3x upper limit of normal: discontinue and refer for hepatological evaluation
Serum creatinine / eGFR
Baseline; monitor if used beyond 8 weeks in patients over 65 or with any renal risk factorsAescin is renally excreted and reports of worsening renal function with IV aescin exist; oral product in patients with borderline renal function warrants monitoring.
flagThreshold: eGFR decline >15% from baseline or creatinine >1.5x baseline: discontinue
Toxicity
Raw horse chestnut seed: toxic; contains esculin which can cause death. Fatal poisonings reported in children who consumed raw seeds or leaf/twig tea.
GI upset, nephrotoxicity, muscle twitching, weakness, ataxia, mydriasis, vomiting, diarrhoea, depression, paralysis, stupor, haemolysis (raw product toxicity)
Activated charcoal if raw product ingested within 1 hour; supportive care; monitor renal and hepatic function; seek emergency care for significant ingestion
Adverse Effects
CYP Metabolism
Animal studies suggest aescin may both inhibit and induce CYP1A2, CYP2C9, and CYP3A4, potentially affecting plasma levels of drugs metabolised by these enzymes. Clinical significance at standard oral doses (300 mg extract / 50 mg aescin BID) is not established. Caution with narrow therapeutic index CYP substrates.
swap_horiz Interactions
Antidiabetic Agents
Class: Antidiabetic
Horse chestnut has documented hypoglycemic effects in preclinical models. Aescin may enhance insulin sensitivity and glucose uptake. Combined use with antidiabetic agents may produce additive blood glucose lowering and hypoglycemia risk.
Monitor blood glucose more frequently when horse chestnut is added to antidiabetic regimens. Educate patients on hypoglycemia symptoms. Dose adjustments to antidiabetic medications may be required.
Loop and Thiazide Diuretics
Class: Diuretic
Horse chestnut has mild diuretic and antioedematous properties via aescin-mediated hyaluronidase and elastase inhibition. Concurrent use with loop or thiazide diuretics may potentiate diuresis leading to electrolyte disturbances and dehydration particularly in elderly patients.
Monitor electrolytes and hydration status in patients combining horse chestnut with diuretic medications. Exercise particular caution in elderly patients and those with cardiac or renal impairment.
Warfarin and Anticoagulants
Class: Anticoagulant
Horse chestnut contains aesculin (a coumarin derivative) with inherent anticoagulant properties, and aescin inhibits platelet aggregation via 5-HT2A receptor modulation. The coumarin content directly potentiates warfarin anticoagulant effect, and additive antiplatelet activity further increases bleeding risk. Standardized extracts have aesculin removed but aescin antiplatelet activity remains.
Avoid concurrent use with warfarin or other anticoagulants unless under close medical supervision. Monitor INR regularly. Use only standardized extracts with aesculin removed. Discontinue horse chestnut at least 2 weeks before surgery.
Antiplatelet Agents
Class: Antiplatelet
Aescin reduces platelet aggregation through inhibition of 5-HT2A receptor-mediated signaling and COX pathway modulation. Additive antiplatelet effects with aspirin or clopidogrel increase the risk of bleeding complications including GI bleeding.
Use with caution in patients on antiplatelet agents. Monitor for unusual bruising or bleeding. Discontinue horse chestnut at least 2 weeks before any surgical procedure.
NSAIDs
Class: Anti-inflammatory (NSAID)
Both horse chestnut and NSAIDs have antiplatelet and anti-inflammatory effects. Combined use additively increases bleeding risk particularly GI bleeding. Both may also reduce renal prostaglandin synthesis, increasing risk of fluid retention and renal toxicity in elderly patients.
Monitor patients taking NSAIDs chronically who add horse chestnut for signs of increased bruising or GI bleeding. Short-term combined use may be acceptable under supervision. Exercise particular caution in elderly patients with renal impairment.
hub Combinations
Synergistic pairings can enhance therapeutic outcomes, while knowing suitable substitutes helps when specific herbs are unavailable or contraindicated.
Synergistic Combinations
3Bilberry
Moderate EvidenceHorse chestnut (aescin — anti-oedematous, venotonic) and Bilberry (anthocyanins — capillary-strengthening, antioxidant) are classically combined for venous and microcirculatory disorders. Bilberry's anthocyanins strengthen capillary walls by cross-linking collagen while aescin improves venous tone.
Combination widely used in European phytotherapy; individual evidence moderate-to-strong for both herbs in venous disorders.
Gotu Kola
Moderate EvidenceHorse chestnut (aescin — venotonic, anti-oedematous) and Gotu Kola (triterpenoids — strengthen venous wall collagen, improve lymphatic drainage) are combined in CVI treatment. Together they address both venous tone and connective tissue integrity of vein walls.
Both herbs have individual RCT evidence for CVI; combination widely used in European phytotherapy for chronic venous disease.
Turmeric
Limited EvidenceCombined for post-surgical oedema and musculoskeletal swelling; horse chestnut reduces oedema via anti-exudative effects while turmeric provides systemic anti-inflammatory action via NF-κB inhibition and COX-2 modulation.
Individual evidence for both; combination use is traditional and widespread in integrative practice.
science Studies
Potential Activity Mechanisms of Aesculus hippocastanum Bark: Antioxidant Effects in Chemical and Biological In Vitro Models
In VitroThis in vitro study characterised the phytochemical composition and antioxidant activity of Aesculus hippocastanum bark extract and its four major constituents (esculin, fraxin, epicatechin, procyanidin A2) against physiologically relevant reactive oxygen species. All analytes demonstrated dose-dependent scavenging of peroxynitrite, hydroxyl radical, and superoxide, with the extract and flavan-3-ol constituents showing particularly strong antioxidant capacity. The findings illuminate the molecular basis for horse chestnut bark activity in vascular conditions associated with oxidative stress. These results provide mechanistic support for the use of horse chestnut bark in conditions connected with vascular insufficiency.
Treatment of patients with venous insufficiency with fresh plant horse chestnut seed extract: a review of 5 clinical studies
Systematic ReviewThis review examined five clinical studies evaluating the fresh-plant horse chestnut seed extract preparation Aesculaforce in patients with chronic venous insufficiency or varicose veins. Four trials in CVI patients and one in varicose vein patients demonstrated effectiveness through objective reduction of lower-leg oedema and subjective alleviation of leg pain, heaviness, and itching. Inhibition of proteolytic degradation of capillary wall proteoglycans by the active constituent escin is proposed as the primary mechanism. The authors concluded that Aesculaforce represents a safe and clinically relevant treatment option for mild-to-moderate CVI and varicose veins.
medication Dosing
capsule
300 mg standardised seed extract (standardised to 50 mg aescin / 16–20% aescin content)
BID (twice daily)
Use only standardised seed extract with aesculin removed. Take with food to minimise GI side effects. Clinical trials support use for up to 16 weeks. For longer-term use, take periodic breaks and monitor liver/renal function.
topical
2% aescin gel
Apply TID–QID to affected areas
Applied topically to varicose veins, haemorrhoids, bruises, post-surgical oedema, and sports injuries. Gently massage into skin. Combination with compression therapy enhances efficacy for CVI.
Disclaimer: This information is largely AI-generated and reviewed by human experts at Evara Health. It is intended for educational and clinical reference purposes only and should not replace professional medical advice.
© 2026 Evara Health. All rights reserved.